Lisata Therapeutics Analyst Ratings
Lisata Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 10/19/2022 | 259.71% | HC Wainwright & Co. | $6 → $15 | Maintains | Buy |
| 日期 | 上行/下行 | 分析公司 | 目標價格變動 | 評級變動 | 之前/當前的評級 |
|---|---|---|---|---|---|
| 10/19/2022 | 259.71% | HC Wainwright & Co. | 6 美元 → 15 美元 | 維護 | 買 |
Lisata Therapeutics Questions & Answers
Lisata Therapeutics 問題與解答
The latest price target for Lisata Therapeutics (NASDAQ: LSTA) was reported by HC Wainwright & Co. on October 19, 2022. The analyst firm set a price target for $15.00 expecting LSTA to rise to within 12 months (a possible 259.71% upside). 1 analyst firms have reported ratings in the last year.
HC Wainwright & Co. 於2022年10月19日公佈了Lisata Therapeutics（納斯達克股票代碼：LSTA）的最新目標股價。該分析公司將目標股價定爲15.00美元，預計LSTA將在12個月內升至12個月內（可能上漲259.71％）。1家分析公司去年公佈了評級。
The latest analyst rating for Lisata Therapeutics (NASDAQ: LSTA) was provided by HC Wainwright & Co., and Lisata Therapeutics maintained their buy rating.
HC Wainwright & Co. 提供了Lisata Therapeutics（納斯達克股票代碼：LSTA）的最新分析師評級，Lisata Therapeutics維持買入評級。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lisata Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lisata Therapeutics was filed on October 19, 2022 so you should expect the next rating to be made available sometime around October 19, 2023.
分析師在進行了廣泛的研究後得出了股票評級，其中包括瀏覽公開財務報表，與Lisata Therapeutics的高管和客戶交談，以及聽取業績電話會議。大多數分析師每三個月做一次這樣的評級，因此每家公司每年應該獲得4次評級。Lisata Therapeutics的最新評級是在2022年10月19日公佈的，因此您應該預計下一個評級將在2023年10月19日左右公佈。
While ratings are subjective and will change, the latest Lisata Therapeutics (LSTA) rating was a maintained with a price target of $6.00 to $15.00. The current price Lisata Therapeutics (LSTA) is trading at is $4.17, which is out of the analyst's predicted range.
儘管評級是主觀的，並且會發生變化，但最新的Lisata Therapeutics（LSTA）評級保持不變，目標股價爲6.00美元至15.00美元。Lisata Therapeutics（LSTA）目前的交易價格爲4.17美元，超出了分析師的預期區間。